Low dose alpha-methyl-para-tyrosine (AMPT) in the treatment of dystonia and dyskinesia
Low dose alpha-methyl-para-tyrosine (AMPT) in the treatment of dystonia and dyskinesia
复制标题
DOI：
10.1176/appi.neuropsych.19.1.65
复制
发表时间：
2007-02-01
影响因子：
2.9
通讯作者：
Salvatore, Michael F.
中科院分区：
文献类型：
--
作者：
Ankenman, Ralph;Salvatore, Michael F.
AMPT（α-甲基-对-酪氨酸）是酪氨酸羟化酶的抑制剂，酪氨酸羟化酶是多巴胺生物合成的限速酶。在临床环境中，AMPT被批准用于治疗嗜铬细胞瘤。肌张力障碍和运动障碍似乎起源于多巴胺通路中多巴胺功能的不一致调节。本文介绍了AMPT治疗某些抗精神病药引起的肌张力障碍或运动障碍的临床疗效的病例史。作者提出，AMPT在迟发性疾病中的特殊用途可能与酪氨酸羟化酶活性的下调有关，而这种下调可能是由抗精神病药诱导的对酪氨酸羟化酶磷酸化的影响引起的。
AMPT (alpha-methyl-para-tyrosine) is an inhibitor of tyrosine hydroxylase, the rate-limiting enzyme in dopamine biosynthesis. In clinical settings, AMPT is approved to treat pheochromocytoma. Dystonias and dyskinesias seem to have their origin in inconsistent regulation of dopamine function in dopamine pathways. This paper presents case histories of the clinical efficacy of AMPT for treating certain individuals with neuroleptic-induced dystonia or dyskinesia. The authors propose that a special utility of AMPT in tardive disorders may be related to a downregulation of tyrosine hydroxylase activity that may be increased by neuroleptic-induced effects on tyrosine hydroxylase phosphorylation.